Sotera Health Q4 net loss $320M on $408M legal reserve; provides 2023 outlook of 5-9% growth

Sotera Health Co

2022-FY EPS reported -$0.83 revenue$1,003,687,000

Q4 net revenues $252M (+4% YoY); net loss $320M ($1.14/share) vs net income $36M in Q4 2021.
Q4 net loss includes $408M reserve for ethylene oxide claims settlement in Cook County, IL.
Q4 adjusted EBITDA $130M (+4% YoY); adjusted EPS $0.25 (+$0.02).
Closed $500M Term Loan B in February 2023.
Full-year 2023 outlook: net revenues and adjusted EBITDA growth of 5% to 9%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sotera Health Co updated its Full-year 2023 guidance (initiated).

Period: Full-year 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

Full-year 2023 outlook Net Revenues and Adjusted EBITDA growth of 5% to 9%

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sotera Health Co filing history →

Source: SEC EDGAR

accession 0001822479-23-000012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.